338 Shares in Axon Enterprise, Inc $AXON Acquired by Conning Inc.

Conning Inc. bought a new position in Axon Enterprise, Inc (NASDAQ:AXON) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 338 shares of the biotechnology company’s stock, valued at approximately $280,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. TCI Wealth Advisors Inc. purchased a new stake in shares of Axon Enterprise in the second quarter worth $214,000. Kentucky Retirement Systems Insurance Trust Fund purchased a new stake in Axon Enterprise in the 1st quarter worth $1,110,000. Quotient Wealth Partners LLC purchased a new stake in Axon Enterprise in the 1st quarter worth $438,000. CX Institutional purchased a new stake in Axon Enterprise in the 1st quarter worth $115,000. Finally, GAMMA Investing LLC increased its stake in Axon Enterprise by 11.8% in the 1st quarter. GAMMA Investing LLC now owns 1,454 shares of the biotechnology company’s stock worth $765,000 after buying an additional 154 shares in the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on AXON shares. Northland Securities set a $800.00 target price on Axon Enterprise in a research report on Tuesday, August 5th. Zacks Research lowered shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 2nd. Piper Sandler initiated coverage on shares of Axon Enterprise in a report on Tuesday, September 23rd. They set an “overweight” rating and a $893.00 price objective for the company. Craig Hallum raised shares of Axon Enterprise from a “hold” rating to a “buy” rating and set a $900.00 price objective for the company in a report on Tuesday, August 5th. Finally, Morgan Stanley set a $885.00 target price on shares of Axon Enterprise and gave the company an “overweight” rating in a research note on Friday, July 11th. Fourteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $841.64.

Axon Enterprise Stock Performance

NASDAQ AXON opened at $703.03 on Friday. The stock has a market capitalization of $55.19 billion, a PE ratio of 173.59, a P/E/G ratio of 27.30 and a beta of 1.41. The business has a 50 day simple moving average of $755.57 and a two-hundred day simple moving average of $713.70. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.95 and a quick ratio of 2.71. Axon Enterprise, Inc has a 1-year low of $422.38 and a 1-year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share for the quarter, beating analysts’ consensus estimates of $1.54 by $0.58. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The firm had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. During the same period last year, the firm posted $1.20 earnings per share. Axon Enterprise’s revenue for the quarter was up 32.6% compared to the same quarter last year. Axon Enterprise has set its FY 2025 guidance at EPS. On average, research analysts predict that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Hadi Partovi acquired 1,358 shares of Axon Enterprise stock in a transaction on Wednesday, August 13th. The shares were bought at an average cost of $740.00 per share, with a total value of $1,004,920.00. Following the completion of the purchase, the director directly owned 237,938 shares of the company’s stock, valued at $176,074,120. The trade was a 0.57% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, President Joshua Isner sold 15,919 shares of the business’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president directly owned 238,379 shares in the company, valued at $177,892,712.54. The trade was a 6.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,932 shares of company stock worth $45,115,616. Insiders own 4.40% of the company’s stock.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.